Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

11.49

21/11 21:00

Market Cap

8.31B

Beta: -

Volume Today

7.11M

Avg: -

Filings Not Available